Solvay's SLV 319 obesity candidate treatment advances in phase II clinical trials
Triggering a milestone payment from co-development and co-commercialization partner Bristol-Myers Squibb
13-Dec-2006 -
Solvay announced that a phase IIB study has started following a decision of the joint development committee for SLV319, which moved this obesity treatment candidate into further phase II clinical trials.
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the ...
Bristol-Myers Squibb
clinical trials
food
+3